AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16825692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12752352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g sachet (micropellets) mesalazine formulation
Number of subjects: 24
Study 12752352 — intervention group
Group type: COMPARATOR
Intervention: Three enteric‐coated tablets (500 mg each, Claversal)
Number of subjects: 24
Study 10772034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary autograft (group A, n = 97)
Number of subjects: 182
Study 10772034 — intervention group
Group type: COMPARATOR
Intervention: Aortic homograft (group H, n = 85)
Number of subjects: 182
Study 9311056 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (2 x 1,000 micrograms/day)
Number of subjects: 1
Study 9311056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 8370292 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 10
Study 8370292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 10
Study 8370292 — intervention group
Group type: COMPARATOR
Intervention: Control group (postoperative cardiac surgery patients)
Number of subjects: 10
Study 3487259 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg bw methylprednisolone
Number of subjects: 60
Study 3487259 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg bw dexamethasone
Number of subjects: 60
Study 3487259 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg hydrocortisone
Number of subjects: 60
Study 3487259 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl as placebo
Number of subjects: 60
Study 3487259 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 60
Study 28956658 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet plus 7 grams of psyllium powder (MoCyllium group)
Number of subjects: 37
Study 28956658 — intervention group
Group type: COMPARATOR
Intervention: Lower carbohydrate diet plus placebo powder (LoCarb group)
Number of subjects: 37
Study 27171828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociception Level (NoL) index
Number of subjects: 58
Study 27171828 — intervention group
Group type: COMPARATOR
Intervention: Other measures of nociception (heart rate, pulse plethysmograph amplitude, noninvasive blood pressure, surgical pleth index)
Number of subjects: 58
Study 24988874 — intervention group
Group type: EXPERIMENTAL
Intervention: CKDu patients
Number of subjects: 0
Study 24988874 — intervention group
Group type: COMPARATOR
Intervention: Non-CKDu subjects
Number of subjects: 0
Study 22668622 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlexanox paste (n = 20)
Number of subjects: 38
Study 22668622 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone paste (n = 18)
Number of subjects: 38
Study 20862938 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with rehabilitation (group A)
Number of subjects: 53
Study 20862938 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training (group B)
Number of subjects: 53
Study 17973165 — intervention group
Group type: EXPERIMENTAL
Intervention: KR (Knowledge of Results)
Number of subjects: 9
Study 17973165 — intervention group
Group type: EXPERIMENTAL
Intervention: KR + instruction
Number of subjects: 9
Study 17973165 — intervention group
Group type: COMPARATOR
Intervention: No KR
Number of subjects: 9
Study 16570889 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-transfusion system with re-infusion of drained blood
Number of subjects: 155
Study 16570889 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone administration before blood re-perfusion
Number of subjects: 155
Study 16570889 — intervention group
Group type: COMPARATOR
Intervention: Standard vacuum drains
Number of subjects: 155
Study 12618164 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-delivered urinary continence promotion programme (training in pelvic floor exercises and adherence-enhancing strategies)
Number of subjects: 348
Study 12618164 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-delivered urinary continence promotion programme
Number of subjects: 348
Study 12618164 — intervention group
Group type: COMPARATOR
Intervention: Usual postpartum care
Number of subjects: 348
Study 10930149 — intervention group
Group type: COMPARATOR
Intervention: AZT 100 mg three times daily plus ddC 0.375 mg three times daily (half dose)
Number of subjects: 111
Study 10930149 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT 200 mg three times daily plus ddC 0.75 mg three times daily (standard dose)
Number of subjects: 111
Study 9513028 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medical intervention including medical management and caregiver education
Number of subjects: 111
Study 9513028 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medical intervention
Number of subjects: 111
Study 8436638 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg bid) under supervision
Number of subjects: 18
Study 8436638 — intervention group
Group type: COMPARATOR
Intervention: Non-compliant patients (8 out of 18)
Number of subjects: 18
Study 8436638 — intervention group
Group type: COMPARATOR
Intervention: BANA test
Number of subjects: 18
Study 2878174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 330
Study 2878174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 31767144 — intervention group
Group type: EXPERIMENTAL
Intervention: High FIO2 (0.80)
Number of subjects: 740
Study 31767144 — intervention group
Group type: COMPARATOR
Intervention: Low FIO2 (0.3)
Number of subjects: 740
Study 31647821 — intervention group
Group type: EXPERIMENTAL
Intervention: ImTeCHO mobile‐phone‐and web‐based application
Number of subjects: 6
Study 31647821 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study 27550537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene-enriched virgin olive oil spray (n = 30)
Number of subjects: 60
Study 27550537 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray (n = 30)
Number of subjects: 60
Study 26022639 — intervention group
Group type: COMPARATOR
Intervention: Binary logistic regression
Number of subjects: 0
Study 26022639 — intervention group
Group type: COMPARATOR
Intervention: Proportional odds regression
Number of subjects: 0
Study 23789370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal suppositories vitaprost plus once a day for 10 days before and after surgery
Number of subjects: 73
Study 23789370 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin 400 mg 2 times a day for 10 days before and after surgery (Control group)
Number of subjects: 73
Study 23789370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal suppositories vitaprost plus
Number of subjects: 73
Study 23789370 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin 400 mg 2 times a day (Control group)
Number of subjects: 73
Study 21972621 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 68
Study 21972621 — intervention group
Group type: COMPARATOR
Intervention: Medication (Enteric-coated aspirin)
Number of subjects: 68
Study 19621668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (group N) for 16 weeks
Number of subjects: 39
Study 19621668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofalcone (group S) for 16 weeks
Number of subjects: 39
Study 16706858 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous-sustained attention (same-point stimuli)
Number of subjects: 0
Study 16706858 — intervention group
Group type: COMPARATOR
Intervention: Exogenous-transient attention (randomised stimuli)
Number of subjects: 0
Study 15533466 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injection (100 to 200 U of Dysport or Botox)
Number of subjects: 13
Study 15533466 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injection
Number of subjects: 13
Study 11816866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 234
Study 11816866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 234
Study 11816866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 9143025 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 0
Study 9143025 — intervention group
Group type: COMPARATOR
Intervention: Hematoxylin‐eosin (HE) stain
Number of subjects: 0
Study 8116561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose as a sweetener
Number of subjects: 0
Study 8116561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 0
Study 8116561 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of fructose
Number of subjects: 0
Study 3426488 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg caffeine
Number of subjects: 30
Study 3426488 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 30
Study 3426488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31714457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (G1) for 12 weeks
Number of subjects: 12
Study 31714457 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (G2)
Number of subjects: 12
Study 29905759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine (GP)
Number of subjects: 236
Study 29905759 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (GT)
Number of subjects: 236
Study 27221328 — intervention group
Group type: EXPERIMENTAL
Intervention: Submandibular gland resection
Number of subjects: 5
Study 25518015 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 64
Study 25518015 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 64
Study 22448451 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based asthma self-management
Number of subjects: 21
Study 22448451 — intervention group
Group type: COMPARATOR
Intervention: Paper-based asthma self-management
Number of subjects: 21
Study 20399993 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of Mycophenolate mofetil (MMF) 500 mg
Number of subjects: 103
Study 20399993 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of Mycophenolate mofetil (MMF) 500 mg
Number of subjects: 103
Study 18397979 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient 1-year intervention program based on exercise, behavior, and nutrition therapy
Number of subjects: 43
Study 18397979 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group of children without substantial weight loss)
Number of subjects: 43
Study 16463851 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-shunted patients
Number of subjects: 68
Study 16463851 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunted patients
Number of subjects: 68
Study 12465731 — intervention group
Group type: EXPERIMENTAL
Intervention: Echo-enhanced power Doppler sonography
Number of subjects: 137
Study 12465731 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound or unenhanced power Doppler sonography
Number of subjects: 137
Study 11272352 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium-192
Number of subjects: 55
Study 11272352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 8600885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 19
Study 8600885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2009843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam, 0.125 mg
Number of subjects: 359
Study 2009843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 6128230 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 0
Study 6128230 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion
Number of subjects: 0
Study 6128230 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin and motilin together infusion
Number of subjects: 0
Study 6128230 — intervention group
Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 0
Study 31348263 — intervention group
Group type: EXPERIMENTAL
Intervention: Real laser acupuncture (LA), 3 sessions a week for 2 weeks
Number of subjects: 40
Study 31348263 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture (LA), 3 sessions a week for 2 weeks
Number of subjects: 40
Study 27641444 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically induced muscle cramps (EIMCs) in the gastrocnemius medialis of one leg (intervention leg, IL)
Number of subjects: 10
Study 27641444 — intervention group
Group type: COMPARATOR
Intervention: Control leg (CL)
Number of subjects: 10
Study 27363928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic site-specific local endometrial injury (LEI), n = 60
Number of subjects: 120
Study 27363928 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group), n = 60
Number of subjects: 120
Study 25279781 — intervention group
Group type: EXPERIMENTAL
Intervention: Onefit P&A
Number of subjects: 0
Study 25279781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Scleral Design (msd)
Number of subjects: 0
Study 25279781 — intervention group
Group type: EXPERIMENTAL
Intervention: Jupiter
Number of subjects: 0
Study 22326775 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of PCV7
Number of subjects: 118
Study 22326775 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of PCV7
Number of subjects: 118
Study 22326775 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two doses of PCV7
Number of subjects: 118
Study 20557905 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model including Charlson index and PCT
Number of subjects: 412
Study 20557905 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation set
Number of subjects: 412
Study 20557905 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 412
Study 20557905 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk groups based on score
Number of subjects: 412
Study 17601990 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic-hyperinsulinemic clamp (1.2 mU x kg(‐1) x min(‐1) insulin)
Number of subjects: 10
Study 17601990 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study 16518992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) levels of 93-99 mg/dl
Number of subjects: 6924
Study 16518992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) levels of 100-125 mg/dl
Number of subjects: 6924
Study 16518992 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI of 23-27.5 kg/m2
Number of subjects: 6924
Study 16518992 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > 27.5 kg/m2
Number of subjects: 6924
Study 16518992 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of type 2 diabetes
Number of subjects: 6924
Study 16518992 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rates by gender
Number of subjects: 6924
Study 12457019 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Mind (ToM) assessment
Number of subjects: 44
Study 12457019 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological measures
Number of subjects: 44
Study 12457019 — intervention group
Group type: EXPERIMENTAL
Intervention: ToM-2 (capacity to comprehend other people's mental states)
Number of subjects: 44
Study 12457019 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent onset of illness, good verbal fluency, low levels of negative and positive symptoms
Number of subjects: 44
Study 10529122 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg of recombinant human IL-10 (rhIL-10) daily for 28 days
Number of subjects: 10
Study 10529122 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg of recombinant human IL-10 (rhIL-10) daily for 28 days
Number of subjects: 10
Study 10529122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8622104 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin (15 mg/kg or 8 mg/kg once daily)
Number of subjects: 252
Study 8622104 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (7.5 mg/kg twice daily)
Number of subjects: 252
Study 8622104 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 252
Study 8622104 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 252
Study 1674105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol (13 to 15 mg per kilogram of body weight per day)
Number of subjects: 146
Study 1674105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 1674105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol
Number of subjects: 146
Study 6156324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 4 microgram/kg/min
Number of subjects: 10
Study 6156324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 8 microgram/kg/min
Number of subjects: 10
Study 31911147 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir (0.5-30 mg single oral dose)
Number of subjects: 30
Study 31911147 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir (10 mg dose)
Number of subjects: 30
Study 31911147 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir (0.5 mg dose)
Number of subjects: 30
Study 30408421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-cement K-wire fixation
Number of subjects: 107
Study 30408421 — intervention group
Group type: COMPARATOR
Intervention: Plate-and-screw system
Number of subjects: 107
Study 28499772 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Advocate Intervention (PAI)
Number of subjects: 102
Study 28499772 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 102
Study 25657175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (baseline treatment)
Number of subjects: 3184
Study 23835929 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 33
Study 23835929 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 33
Study 21362575 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion (10% fish oil, 50% medium‐chain triacylglycerols, 40% soybean oil)
Number of subjects: 47
Study 21362575 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (standard preparation, 50:50 medium‐chain triacylglycerols: soybean oil)
Number of subjects: 47
Study 18640856 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen extended-release (APAP ER) 3900 mg daily
Number of subjects: 403
Study 18640856 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 12.5 mg daily
Number of subjects: 403
Study 18640856 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 25 mg daily
Number of subjects: 403
Study 17538978 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy with aromatase inhibitors (anastrozole 1 mg/day or exemestane 25 mg/day for 3 months)
Number of subjects: 121
Study 17538978 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (doxorubicin 60 mg/m(2) with paclitaxel 200 mg/m(2) for four 3-week cycles)
Number of subjects: 121
Study 14738791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (500 mg per day for 5 days)
Number of subjects: 233
Study 14738791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 5 days)
Number of subjects: 233
Study 15801935 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF3381 400 mg twice daily
Number of subjects: 48
Study 15801935 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF3381 100 mg twice daily
Number of subjects: 48
Study 15801935 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF3381 200 mg twice daily
Number of subjects: 48
Study 15801935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10477360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐arginine (CHO/AA) supplement (1 g carbohydrate/kg body mass and 0.08 g arginine‐hydrochloride/kg body weight)
Number of subjects: 12
Study 10477360 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) supplement (1 g carbohydrate/kg body weight)
Number of subjects: 12
Study 8916825 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg-1 intravenously
Number of subjects: 97
Study 8916825 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms.kg-1 intravenously
Number of subjects: 97
Study 8916825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 1886351 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 1% (Indoptic)
Number of subjects: 40
Study 1886351 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% (Ocuflur)
Number of subjects: 40
Study 6407352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 213
Study 6407352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus oxymetholone
Number of subjects: 213
Study 6407352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 213
Study 30837170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine with 45 μg of LTh(αK)
Number of subjects: 36
Study 30837170 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (22.5 μg of influenza HA antigen alone)
Number of subjects: 36
Study 29061153 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Group (LG) - 100 persons
Number of subjects: 195
Study 29061153 — intervention group
Group type: COMPARATOR
Intervention: Small Group (SG) - 20 persons (4 groups)
Number of subjects: 195
Study 27586538 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-amlodipine (2.5-5 mg)
Number of subjects: 172
Study 27586538 — intervention group
Group type: COMPARATOR
Intervention: Conventional amlodipine (5-10 mg)
Number of subjects: 172
Study 24952863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7062
Study 24952863 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7062
Study 22427146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozil Intelligent Phaco (IP) torsional mode
Number of subjects: 60